Last updated: February 24, 2026
What is NDC 00904-7042?
NDC 00904-7042 refers to a specific drug product listed in the National Drug Code (NDC) system. The code indicates the manufacturer, product details, dosage forms, and packaging. Based on available data, NDC 00904-7042 corresponds to Dextroamphetamine and Amphetamine Extended-Release Capsules, commonly marketed under brand names like Adderall XR.
Market Landscape
Demand Drivers
- Therapeutic Use: ADHD and narcolepsy treatment.
- Market Size: The US ADHD drug market was valued at approximately $12.3 billion in 2022.
- Growth Rate: Compound annual growth rate (CAGR) of around 6%, driven by increased diagnosis and approval for broader age groups.
Competitive Environment
- Major Players: Shire (AbbVie), Teva, Mylan, and Sun Pharma.
- Market Share: The product holds an estimated 40-50% share among prescription stimulants for ADHD.
- Product Lineup: Competitors include methylphenidate formulations, other amphetamine-based agents, and non-stimulant medications like atomoxetine.
Regulatory Factors
- FDA Approvals: The drug has FDA approval with no recent major label changes.
- Reimbursement: Covered by Medicare, Medicaid, and private insurers; reimbursement rates influence sales.
Price Analysis
Current Pricing Data
| Pricing Parameter |
Value |
Source/Notes |
| Average Wholesale Price (AWP) per unit |
$4.50 – $5.00 |
CMS drug pricing database [1] |
| Estimated Retail Price (e.g., cash-pay) |
$10 – $15 |
Pharmacy checkout data [2] |
| Insurance Reimbursement Rate |
~$4 |
Based on typical Medicaid or commercial plans [3] |
Historical Price Trends
- Pre-Generic Period: Prices fluctuated between $5.50 and $7.50 per capsule.
- Post-Generic Entry: Prices declined by approximately 20-30%, stabilizing around current levels.
- Pricing Variability: Regional differences and pharmacy discounts cause variability.
Price Escalation Factors
- Supply Chain Disruptions: Potential for price increases amid manufacturing constraints.
- Regulatory Changes: Schedule II reclassification impacts manufacturing and distribution costs.
- Market Demand: Steady growth sustains pricing within current ranges.
Price Projection
Short-term (1–2 years)
- Stable Pricing: Expect prices to remain within the current $4.50–$5.00 AWP range.
- Impact Factors: No significant policy shifts or supply disruptions expected. Slight fluctuations due to inflation or pharmacy margin adjustments.
Mid-term (3–5 years)
- Moderate Increase: Possible 3-5% annual price increase driven by inflation and cost of manufacturing.
- Market Penetration: Growing adoption in adolescent and adult populations could increase volume sales but not dramatically influence unit price.
Long-term (5+ years)
- Price Ceiling: Likely stabilization around current levels absent major regulatory changes.
- Emerging Alternatives: Development of new formulations or non-stimulant therapies could impact demand and pricing.
Regulatory & Policy Impact
- Reimbursement Policies: Shifts towards value-based pricing may influence actual sales revenue.
- Controlled Substances Regulations: Stricter controls may increase distribution costs, influencing net price.
Key Market Risks
- Generic Competition: Increased generic production could sustain lower price points.
- Policy Changes: Potential for tighter prescribing regulations impacting volume.
- Supply Chain Issues: Raw material shortages or manufacturing delays could temporarily inflate prices.
Conclusion
NDC 00904-7042, identified as extended-release dextroamphetamine and amphetamine capsules, operates in a mature and competitive market with steady demand. Prices have stabilized post-generic entry, with moderate upward pressure expected over the next five years primarily due to inflation rather than major market shifts.
Key Takeaways
- The product maintains a strong market position with approximately 40-50% share in stimulant therapy.
- Current wholesale prices range from $4.50–$5.00 per capsule.
- Prices are projected to increase modestly, 3-5% annually, over the mid-term.
- Competition from generics and emerging therapies could influence future pricing and market share.
- Regulatory, reimbursement, and supply chain factors pose ongoing risks to pricing stability.
FAQs
Q1: How does the entry of generics impact pricing?
A: It typically causes a significant price reduction; the current stabilization reflects balancing the loss of brand premiums with market volume.
Q2: What are the main competitors?
A: Methylphenidate formulations (e.g., Ritalin, Concerta) and non-stimulant alternatives like atomoxetine.
Q3: How does regulatory policy influence pricing?
A: Stricter scheduling and prescribing controls can limit sales volume, indirectly impacting revenue and pricing strategies.
Q4: Are there regional pricing differences?
A: Yes, retail and wholesale prices vary by state and pharmacy, influenced by local market dynamics.
Q5: What factors could accelerate price increases?
A: Supply shortages, regulatory changes increasing manufacturing costs, or inflationary pressures.
References
[1] Centers for Medicare & Medicaid Services. (2023). Drug Pricing Data.
[2] IQVIA. (2023). Retail Pharmacy Data.
[3] DrugChannels. (2023). Reimbursement and Pricing Reports.
